Find a Clinical Trial | Tufts Medicine

Filter

Showing 11 - 20 out of 22

ANHL1931

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Lymphoma

All genders

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Learn more

A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727

ASTX727-07 - A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

Acute myeloid leukemia (AML)

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

CAR-T detection by IVFC

CAR-T detection by label-free invitro flow cytometry

Lymphoma

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

A Long COVID-19 Observational Pilot Study Using Wearable Devices

Detection and Risk Assessment in Post COVID-19 Infection – A Long COVID-19 Observational Pilot Study

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

COVID-19 Survivors Registry

National COVID-19 Survivors Registry

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

PBCAR0191

Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

Armata Bacteriophage Study; disArm Study

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus.

Bacterial infection, Staphylococcus aureus

All genders

18-100

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

Embrace

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination with ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years and Older with a History of Urinary Tract Infection in the Past 2 Years

Urinary tract infections

All genders

60+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

RECOVER VITAL

RECOVER‐VITAL: A Platform Protocol for Evaluation of
Interventions for Viral Persistence, Viral Reactivation,
and Immune Dysregulation in Post‐Acute Sequelae of
SARS‐CoV‐2 Infection (PASC)

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

S1925

S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Chronic lymphocytic leukemia (CLL), Lymphoma

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more